| ID Source | ID |
|---|---|
| PubMed CID | 114869 |
| CHEMBL ID | 1200329 |
| CHEBI ID | 9609 |
| SCHEMBL ID | 41199 |
| MeSH ID | M0081341 |
| Synonym |
|---|
| ds-103282 ch |
| nvd-422 |
| ds-103282 |
| an-021a |
| tizanidine hydrochloride, >=98% (hplc), powder |
| zanaflex |
| 2,1,3-benzothiadiazol-4-amine, 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-, monohydrochloride |
| 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole hydrochloride |
| ds 103-282 |
| 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole monohydrochloride |
| tizanidine hcl |
| tizanidine hydrochloride |
| MLS001333593 |
| D00776 |
| tizanidine hydrochloride (jp17/usp) |
| 64461-82-1 |
| zanaflex (tn) |
| MLS001306412 |
| smr000499584 |
| MLS001076686 |
| T2527 |
| 5-chloro-4-[(4,5-dihydro-1h-imidazol-2-yl)amino]-2,1,3-benzothiadiazole hydrochloride |
| CHEMBL1200329 |
| tizanidine (as hydrochloride) |
| ds-103-282 |
| an021 , |
| an-021 |
| FT-0656022 |
| 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride |
| AKOS005267234 |
| EN300-49853 |
| unii-b53e3nmy5c |
| tizanidine hydrochloride [usan:usp:jan] |
| b53e3nmy5c , |
| 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzo[c][1,2,5]thiadiazol-4-amine hydrochloride |
| LP01114 |
| tizanidine hydrochloride [ep monograph] |
| tizanidine hydrochloride [usp impurity] |
| tizanidine hydrochloride [who-dd] |
| tizanidine hydrochloride [vandf] |
| tizanidine hydrochloride [jan] |
| tizanidine hydrochloride [usan] |
| tizanidine hydrochloride [mi] |
| tizanidine hydrochloride [mart.] |
| tizanidine hydrochloride [orange book] |
| 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole monohydrochloride. |
| tizanidine hydrochloride [usp monograph] |
| S1437 |
| CCG-222418 |
| CCG-220602 |
| HY-B0194A |
| tizanidine (hydrochloride) |
| NC00654 |
| SCHEMBL41199 |
| KS-1120 |
| 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazolehydrochloride |
| NCGC00261799-01 |
| tox21_501114 |
| DTXSID9046990 , |
| ZWUKMNZJRDGCTQ-UHFFFAOYSA-N |
| 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine;hydrochloride |
| tizanidinehydrochloride |
| 5-(chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride |
| 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazole-4-amine hydrochloride |
| ds103-282 |
| AC-22546 |
| mfcd00798231 |
| SR-01000765392-4 |
| sr-01000765392 |
| tizanidine hydrochloride, united states pharmacopeia (usp) reference standard |
| D70434 |
| tizanidine hydrochloride, 500 mug/ml in methanol, certified reference material |
| tizanidine hydrochloride, european pharmacopoeia (ep) reference standard |
| CHEBI:9609 |
| SW199068-2 |
| 64461-82-1 (hcl) |
| 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-8-thia-7,9-diazabicyclo(4.3.0)nona-2,4,6,9-tetraen-5-amine |
| BCP28540 |
| brn0618691 |
| AMY18121 |
| Q27274381 |
| tizanidine * hcl |
| tizanidine hydrochloride 100 microg/ml in acetonitrile |
| 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzo[c][1,2,5]thiadiazol-4-aminehydrochloride |
| 74113-36-3 |
| (5-chloro-2,1,3-benzothiadiazol-4-yl)-(4,5-dihydro-1h-imidazol-2-yl)azanium;chloride |
| BT164478 |
| tizanidine hydrochloride- bio-x |
| tizanidine hydrochloride (usp monograph) |
| tizandine |
| tizanidine hydrochloride (ep monograph) |
| 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine monohydrochloride |
| dtxcid7026990 |
| tizanidine hydrochloride (usan:usp:jan) |
| tizanidne hydrochloride |
| tizanidine hydrochloride (usp impurity) |
| tizanidine hydrochloride (mart.) |
| Z594284192 |
| Class | Description |
|---|---|
| benzothiadiazole | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||